Meta-Analysis



Effects of high-dose versus low-dose proton pump inhibitors for treatment of gastrointestinal ulcer bleeding: a meta-analysis of randomized controlled trials Journal of International Medical Research 50(4) 1–11 © The Author(s) 2022 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/03006605211067396 journals.sagepub.com/home/imr



Wei Zhu¹,*, Liang Chen²,* , Jian Zhang³,* and Pei Wang³

Abstract

Background: We performed a meta-analysis to compare the effects of high-dose (80 mg/day) versus low-dose (40 mg/day) proton pump inhibitors (PPIs) on gastrointestinal ulcer bleeding. **Methods:** We retrieved studies of randomized controlled trials of PPIs administered according to different schedules for the treatment of gastrointestinal ulcer bleeding from Medline, Embase, Web of Science, Clinical Trials, and the Cochrane Database in April 2020.

Results: Nine randomized controlled trials including 2329 patients were included in this metaanalysis. There were no significant differences in the incidences of re-bleeding, operation intervention, postoperative mortality, and length of hospital stay between the low-dose and high-dose groups. However, the blood transfusion volume was significantly higher in the high-dose group. **Conclusion:** Compared with low-does PPIs, high-dose PPIs had no effect on the incidence of re-bleeding, operation intervention, or postoperative mortality, and did not reduce hospital stay in patients treated with endoscopic hemostasis for gastrointestinal bleeding.

¹Department of Gastrointestinal Vascular Pediatric Surgery, Dongfeng General Hospital of National Medicine, Hubei University of Medicine, Shiyan, Hubei, P.R. China ²Department of Gastrointestinal Surgery, Affiliated Huadu Hospital of Southern Medical University (People's Hospital of Huadu District), Guangzhou, Guangdong, P.R. China ³Department of Gastrointestinal Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei, P.R. China

*These authors contributed equally to this work.

Corresponding author:

Pei Wang, Department of Gastrointestinal Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442200, P.R. China. Email: 3033556458@qq.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Keywords

Proton pump inhibitor, gastrointestinal ulcer bleeding, intravenous drip, meta-analysis, drug dose, blood transfusion

Date received: I September 2021; accepted: 29 November 2021

Introduction

Gastrointestinal bleeding is a common clinical emergency caused by various factors, including gastrointestinal ulcers, tumors, stress, and trauma. Gastrointestinal ulcers are one of the most common causes of gastrointestinal bleeding, with digestive tract ulcers accounting for about 50% of cases.^{1,2} Endoscopic hemostasis is an effective method for treating bleeding caused by digestive tract ulcers, and has been shown to significantly reduce the rebleeding and mortality rates in patients.^{3–5} However, gastric acid can affect the formation of blood clots and increase the risk of rebleeding,⁶ and controlling the formation of gastric acid after endoscopic hemostasis is a key factor in reducing the occurrence of rebleeding.

Proton pump inhibitors (PPIs) are commonly used to inhibit gastric acid secretion and increase gastric pH. They can inhibit basic gastric acid and histamine secretion, inhibit acid secretion stimulated by food, and block the final channel of gastric acid secretion.^{6,7} PPIs are benzimidazole drugs that combine irreversibly with and inactivate the proton pump, thus inhibiting its acid-secretion function.⁸ However, PPIs only inhibit the activated proton pump in the acidic environment of secretory tubules and have no inhibitory effect on the static proton pump, and also depend on covalent binding to the H⁺-K⁺-ATPase, making their action relatively slow.9,10 Although these factors mean that high-dose PPI regimens are often used in the clinic,¹¹ some results have shown that high-dose PPIs may have a similar acid-inhibitory effect to low-dose PPIs.¹¹

In this study, we systematically evaluated the effects of high-dose (80 mg/day) versus low-dose (40 mg/day) PPIs on the prognosis of patients with gastrointestinal ulcer bleeding, to provide evidence to support the choice of PPI administration schedule in patients with gastrointestinal ulcer bleeding.

Methods

Search strategy

We performed a systematic review and meta-analysis, reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Supplementary table 1). Articles reporting randomized controlled trials (RCTs) of different administration schedules of PPIs for the treatment of gastrointestinal ulcer bleeding were retrieved from PubMed, Embase, Web of Science, Clinical Trials. and the Cochrane Database from the start of the database up to April 2020, using keywords "Proton the Pump Inhibitors" [MeSH] OR "PPI" [MeSH] "Esomeprazole" OR [MeSH] OR "Lansoprazole" [MeSH] OR "Omeprazole" [MeSH] OR "Pantoprazole" [MeSH] AND "Gastrointestinal bleeding" [MeSH] OR "Peptic Ulcer Bleeding" [MeSH] AND "Randomized Controlled Trial" [MeSH] OR "RCT". The search strategy is shown in detail in Supplementary list 1.

This was a meta-analysis of previously published studies, and ethical approval

and informed consent were therefore not required.

Inclusion and exclusion criteria

We included RCTs written in English, regardless of whether or not specific random allocation methods were mentioned and distribution scheme hiding and blinding methods, with no limits on the date of publication. We included studies of patients who received endoscopic hemostasis within 24 hours after admission and who were treated with PPIs for bleeding caused by digestive tract ulcers. Studies were not limited by age or sex. The observation group included patients treated with continuous high-dose PPIs, i.e. an initial dose of 80 mg followed by 8 mg/hour for 72 hours. Patients in the control group received a routine dose of PPIs by intermittent intravenous drip. No other drugs were used in either group. The main outcome indicator was the incidence of postoperative re-bleeding (including hematemesis or hematochezia), and secondary indicators included surgical intervention, re-transfusion, length of hospital stay, and postoperative mortality.

We entered the retrieved literature from the databases into EndNote and eliminated duplicate documents. We then read the titles and abstracts according to the PICOS principles for preliminary screening, and then read the full texts of the relevant articles. We excluded articles reporting reviews, case reports, letters, minutes of meetings, animal trials, patients without endoscopic hemostasis, and patients with gastrointestinal bleeding due to stress, hematopathy, and malignant neoplasms.

Data extraction and methodological quality evaluation

The data were extracted and evaluated by two staff members during the study period and any differences were resolved by negotiation. We extracted the following data: (1) title, name of first author, and date of publication; (2) numbers of cases in high-dose and low-dose groups, types and methods of drug administration, including dosage; (3) Incidences of primary of postoperative rebleeding outcome (including hematemesis or hematochezia), and secondary indicators including surgical intervention, re-transfusion, length of hospital stay, and postoperative mortality. The quality of the studies was evaluated using the Cochrane risk of bias (ROB 2.0) tools.

Statistical analysis

This meta-analysis was conducted using RevMan 5.3 software provided by the Cochrane Cooperative Network. The effects of continuous data were presented as mean difference (MD), the effects of binary data as odds ratios (ORs), and the combined effect was expressed by each effect amount with 95% confidence intervals (CIs). The validity of the fixed-effect model was assessed by study heterogeneity within each pairwise comparison. The degree of heterogeneity was quantified using Cochran's Q and Higgin's I² statistic, before the combined data were subjected to meta-analysis. If there was no heterogeneity $(P \ge 0.05 \text{ or } I^2 \le 50\%)$, the combined statistics were calculated using a fixed effect model. If there was significant heterogeneity among the groups (P < 0.05 or $I^2 > 50\%$),¹² the source of heterogeneity was analyzed and subgroup analysis of the factors causing the heterogeneity was carried out.

Results

Literature search results

A flow chart of the literature search is shown in Figure 1. After removing 21 duplicate studies, we identified 876 studies using the above search strategy. A further 838




Figure 1. Flow diagram of the study selection process.

were excluded as case reports, editorials, letters, meeting abstracts, review articles, and non-human studies through screening of the titles and abstracts. The full texts of the remaining 38 citations were assessed in more detail to determine their eligibility. Among these, 16 studies were excluded because they were not RCTs, two were excluded as guidelines or recommendations, five were excluded due to a lack of available data, five were excluded as citations or news releases, and three were excluded as metaanalyses. The remaining nine studies were included in the final data synthesis.¹³⁻²¹ The characteristics of the included studies are shown in Table 1.

Study quality and risk bias

We evaluated the risk of bias for each study using Cochrane RevMan 5.3 software

(Figure 2). Most studies showed a low risk of bias. We found no risk of bias.

Primary outcome: rebleeding

The incidences of rebleeding in patients treated with high-dose compared with low-dose PPIs for gastrointestinal ulcer bleeding are shown in Figure 3a. The incidence of re-bleeding was reported in all nine included articles, including 2321 patients. The results of heterogeneity testing showed no significant heterogeneity among the studies (P=0.13, $I^2 = 36\%$), and there was no significant difference in the incidence of re-bleeding between the two groups (OR = 0.87, 95% CI = 0.65 to 1.15).

Secondary outcomes

The results of heterogeneity testing for operation intervention showed no

		Number of	Number of participants	Intensive regimen		Standard regimen		
Author (year)	Blinding	Intensive regimen	Standard regimen	Treatment	Mode of administration	Treatment	Mode of administration	Outcomes
Andriulli et al. (2008) ²⁰	Double-blind	238	236	Omeprazole or pantoprazole	Start: 80 mg, 8 mg/h for 3 days: Maintenance: oral 20 mg, 2 times a day. continued until discharge	Omeprazole or pantoprazole	Start: 40 mg, 2 times a day for 3 days; Maintenance: oral 20 mg, 2 times a day, continued until	1), 2), 3), 4), 5)
Masjedizadeh et al. (2014) ²¹	Double-blind	83	83	Pantoprazole	Start: 80 mg, 8 mg/h for 3 days; Maintenance: oral 40 mg, once a day for 27 days	Pantoprazole	discharge Start: 40 mg, 4 mg/ h for 3 days; Maintenance: oral 40 mg, once a day	1), 2), 3), 5)
Chen et al. (2012) ¹⁵	Double-blind	001	101	Pantoprazole	Start: 80 mg, 8 mg/h for 3 days; Maintenance: oral 40 mg, once a day for 27 days	Pantoprazole	for 27 days Start: 40 mg, 2 times a 1), 2), 3), 4), 5) day for 3 days; Maintenance: oral 40 mg, once a day	1), 2), 3), 4), 5)
Yüksel et al.	Double-blind	48	49	Pantoprazole	Start: 80 mg, 8 mg/h for	Pantoprazole	tor 2/ days Start: 40 mg, 2 times a	1), 2), 3), 4), 5)
(2008) Udd et al. (2001) ¹³	Double-blind	69	73	Omeprazole	s days Start: 80 mg, 8 mg/h for 3 days, Maintenance: oral 40 mg, once a day for 27 days	Omeprazole	day for 3 days Start: 20 mg, once a day for 3 days; Maintenance: oral 40 mg, once a day	1), 2), 3), 4), 5)
Liu et al. (2012) ¹⁷	Double-blind	419	456	Omeprazole or esomeprazole	Start: 80 mg, 8 mg/h for 3 days; Maintenance: oral 20 mg, 2 times a day, continued until discharge	Omeprazole or esomeprazole	for 27 days Start: 40 mg, 2 times a day for 3 days; Maintenance: oral 20 mg, 2 times a day, continued until	1), 2), 3), 4), 5)
Chan et al. (2011) ¹⁴	Double-blind	61	61	Omeprazole	Start: 80 mg, 8 mg/h for 3 days; Maintenance:	Omeprazole	discharge Start: 40 mg, once a day for 3 days;	1), 2), 3), 4), 5)

		Number of	Number of participants	Intensive regimen	E	Standard regimen		
Author (year)	Blinding	Intensive regimen	Standard regimen	Treatment	Mode of administration	Treatment	Mode of administration	Outcomes
					oral 40 mg, once a day		Maintenance: oral	
					for 28 days		40 mg, once a day for 28 days	
Hsu et al. (2010) ¹⁶	Double-blind	60	60	Pantoprazole	Start: 80 mg, 8 mg/h for 3 days	Pantoprazole	Start: 40 mg every 6 h for 3 days	1), 2), 3)
Songür et al. (2011) ¹⁸	Double-blind	66	66	Omeprazole	Start: 80 mg, 8 mg/h for 3 days; Maintenance:	Omeprazole	Start: 40 mg, 2 times a day for 3 days;	l), 2), 3), 4), 5)
					oral 20 mg, 2 times a day for 30 days		Maintenance: oral 20 mg, 2 times a day for 30 days	
Incidences of 1) re	:-bleeding; 2) ope	stion interve	antion; 3) bloo	d transfusion; 4) h	Incidences of 1) re-bleeding: 2) operation intervention; 3) blood transfusion; 4) hospital stay; 5) postoperative mortality.	mortality.		

significant heterogeneity among the studies $(P = 0.74, I^2 = 0\%)$, and there was no significant difference in operation intervention between the two groups (OR = 0.86, 95% CI = 0.55 to 1.37) (Figure 3b).

The incidence of postoperative mortality was reported in all nine articles, including 2321 patients. Heterogeneity testing showed no significant heterogeneity among the studies (P=0.59, I²=0%), and there was no significant difference in the incidence of postoperative mortality between the two groups (OR=0.78, 95% CI=0.43 to 1.40) (Figure 3c).

The length of hospital stay was reported in six articles. There was no significant heterogeneity among the studies according to heterogeneity testing (P=0.39, $I^2=4\%$), and the results showed no significant difference in the incidence of re-bleeding between the two groups (MD=0.33, 95% CI = -0.03 to 0.70) (Figure 3d).

Seven articles including 1326 patients reported the volume of blood transfusion. Heterogeneity testing showed no significant heterogeneity among the studies (P = 0.74, $I^2 = 0\%$). The results showed that the blood transfusion volume was significantly higher in the high-dose group (MD = 0.36, 95% CI = 0.11 to 0.61, P = 0.005) (Figure 3e).

Publication bias

There was no significant publication bias (Table 2).

Discussion

Endoscopic hemostasis is an effective treatment method for gastrointestinal ulcer bleeding. However, although it can reduce the incidence of re-bleeding and mortality to some extent, the continuous action of gastric acid may cause the clot to fall off, leading to re-bleeding.²² Numerous studies have shown that decreasing the acidity and increasing the pH of gastric acid after

Table 1. Continued.




Figure 2. Risk of bias of the included randomized controlled trials. +, low risk; -, high risk; ?, unclear risk.

surgery can significantly reduce the incidence of re-bleeding after endoscopic hemostasis.^{15,16,23} Gastric acid excretion in the stomach is proportional to the number of parietal cells, which also determines the number of active proton pumps.²⁴ Recent studies have shown that intravenous PPIs can significantly reduce the incidence of adverse events after surgery, but the optimal dosage and route of administration are still controversial.

The recommended high-dose PPI regimen is 80 mg + 8 mg/hour, i.e. an initial large dose (80 mg) of intravenous PPI followed by a continuous infusion of 8 mg/hour for 72 hours, which is referred to as the "808" treatment scheme.²⁵ In the treatment of peptic ulcer bleeding using this scheme, the stability of the PPI used for continuous intravenous drip is closely related to the pH of the drug solution, and the stability of the solution is also influenced by metal ions, light, temperature, and even the packing materials used in the infusion.^{26,27} The stability of the drug and its solution are therefore important considerations when high doses of PPIs are used, as in the "808" protocol, and the preparation requirements and storage conditions of the PPI must be understood. Continuous intravenous administration of PPIs also requires prolonged opening of the venous passage and nursing care by specialist nurses, and thus increases drug use and the risk of adverse drug reactions. After achieving the intended therapeutic purpose, it is therefore worth considering if the treatment can be reduced or provided on-demand.

PPI infusion therapy has been reported to be superior to placebo for the treatment of gastrointestinal ulcer bleeding.^{28–30} The aim of the current study was to compare high-dose versus low-dose PPIs in terms of the prognostic effects of the two methods on disease outcome and postoperative complications in patients with gastrointestinal (a)

	Intensive		Standard I			Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total		M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
Andriulli 2008	28	238	19	236	16.3% 9.4%	1.52 [0.83, 2.81]		
Chan 2011 Chen 2012	2	97	10	96	4.6%	0.17 [0.04, 0.83] 1.20 [0.35, 4.07]		
Hsu 2010	6	60	5	90	4.0%	1.22 [0.35, 4.07]		
Liu 2012	27	419	50	456	43.5%	0.56 [0.34, 0.91]		
Masiedizadeh 2014	6	419	50	450	45.5%	1.22 [0.36, 4.15]		
Songür 2011	11	66	12	66	9.7%	0.90 [0.37, 2.21]		
Udd 2001	8	69	6	73	5.0%	1.46 [0.48, 4.46]		
Yüksel 2008	4	48	3	49	2.6%	1.39 [0.29, 6.59]		
Total (95% CI)		1141		1190	100.0%	0.87 [0.65, 1.15]		-
Total events	98		115	1100	100.0%	0.87 [0.05, 1.15]		
Heterogeneity: Chi ² = Test for overall effect			I ² = 36%				0.01	0,1 10 100 Favours [Intensive Regimen] Favours [Standard Regimen]
(b)								
Study or Subgroup	Intensive Events	Regimen Total	Standard Events		Moight	Odds Ratio M-H, Fixed, 95% Cl		Odds Ratio M-H, Fixed, 95% Cl
Andriulli 2008	Events 3	238	Events 1	236	2.5%	3.00 [0.31, 29.05]	-	M-H, FIXEG, 95% CI
Chan 2011	3	238	4	230	9.9%	0.24 [0.03, 2.19]		
Chen 2012	0		0	96	9.9%	Not estimable		
Hsu 2010	1	60	0	90	1.2%	3.05 [0.12, 76.39]		
Liu 2012	13		19	456	44.5%	0.74 [0.36, 1.51]		
Masjedizadeh 2014	13		19	456	44.5%	0.74 [0.36, 1.51]		
Songür 2011	2		3	66	7.3%	0.66 [0.11, 4.06]		
Udd 2001	2 5		3	73	6.8%	1.82 [0.42, 7.94]		
Yüksel 2008	2		2	49	4.8%	1.82 [0.42, 7.94]		
Total (95% CI)		1141			100.0%	0.86 [0.55, 1.37]		
Total events	35		42	1180	100.0%	0.80 [0.55, 1.37]		T
Heterogeneity: Chi ² = Test for overall effect:			°=0%				0.01	0.1 1 10 10
restion overall ellect.	2 - 0.03 (r	- 0.55)						Favours [Intensive Regimen] Favours [Standard Regimen]
(c)	Intensive	Regimen	Standard I	Regimen		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total		M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Andriulli 2008	5	238	5	236	19.6%	0.99 [0.28, 3.47]		
Chan 2011	0	61	2	61	9.9%	0.19 [0.01, 4.12]	+	
Chen 2012	3	97	1	96	3.9%	3.03 [0.31, 29.67]		
Hsu 2010	1	60	0	60	1.9%	3.05 [0.12, 76.39]		
Liu 2012	1	419	6	456	22.9%	0.18 [0.02, 1.50]		
Masjedizadeh 2014	4	83	5	83	19.0%	0.79 [0.20, 3.05]		
Songür 2011	3	66	2	66	7.6%	1.52 [0.25, 9.43]		
Udd 2001 Yüksel 2008	2	69 48	4	73	15.1%	0.51 [0.09, 2.91] Not estimable		-
Tuksel 2008	0	40	0	49		Notesumable		
Total (95% CI)		1141	05	1180	100.0%	0.78 [0.43, 1.40]		-
			25				-	
Total events	19	-						01 1 10 10
	5.58, df = 7		^e = 0%				0.01	
Total events Heterogeneity: Chi ^a = Test for overall effect	5.58, df = 7		*= 0%				0.01	UI 10 Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ^a = Test for overall effect	5.58, df = 7 Z = 0.84 (P	= 0.40)		d Regime		Mean Difference		Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ² = Test for overall effect.	5.58, df = 7 Z = 0.84 (P	= 0.40) Regimen	Standar	d Regimen SD To		Mean Difference		Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference
Total events Heterogeneity: Chi ^a = Test for overall effect: (d) Study or Subgroup	5.58, df = 7 Z = 0.84 (P Intensive Mean	= 0.40) Regimen SD Tota	Standar I Mean	SD To	tal Weig	ht IV, Fixed, 95%	e Cl	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ^a = Test for overall effect. (d) <u>Study or Subgroup</u> Andriulli 2008	5.58, df = 7 Z = 0.84 (P Intensive Mean 7.3	= 0.40) Regimen <u>SD Tota</u> 4.4 23	Standar <u>I Mean</u> 8 6.6	SD To 3.7 2	tal Weig 36 24.6	ht IV, Fixed, 95% % 0.70 [-0.03, 1.4	e CI 3]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference
Total events Heterogeneity: Chi ^a = Test for overall effect:	5.58, df = 7 Z = 0.84 (P Intensive Mean 7.3 5.2	= 0.40) Regimen <u>SD Tota</u> 4.4 23: 2.1 6	Standar <u>I Mean</u> 8 6.6 1 5.9	SD To 3.7 2 6.4	tal Weig 36 24.6 61 4.6	ht IV, Fixed, 95% % 0.70 [-0.03, 1.4 % -0.70 [-2.39, 0.9	e <u>Cl</u> 3] 9]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference
Total events Heterogeneity. Chi ^a = Test for overall effect:	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.2 7.1	Regimen SD Tota 4.4 23: 2.1 6 7.8 9	Standar <u>Mean</u> 8 6.6 1 5.9 7 5.9	SD To 3.7 2 6.4 2.3	tal Weig 36 24.6 61 4.6 96 5.0	Int IV, Fixed, 95% % 0.70 [-0.03, 1.4 % -0.70 [-2.39, 0.9 % 1.20 [-0.42, 2.8	e Cl 3] 9] 2]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference
Total events Heterogeneity. Chi ^a = Test for overall effect.	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.2 7.1 5.9	Regimen SD Tota 4.4 23 2.1 6 7.8 9 2.8 6	Standar <u>Mean</u> 8 6.6 1 5.9 7 5.9 6 5.4	<u>SD</u> To 3.7 2 6.4 2.3 1.7	tal Weig 36 24.6 61 4.6 96 5.0 66 21.1	Int IV, Fixed, 95% % 0.70 [-0.03, 1.4 % -0.70 [-2.39, 0.9 % 1.20 [-0.42, 2.8 % 0.50 [-0.29, 1.2	e CI 3] 9] 2] 9]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference
Total events Heterogeneity. Chi ^a = Test for overall effect:	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.2 7.1 5.9 5.7	Regimen SD Tota 4.4 23: 2.1 6 7.8 9	Standar Mean 8 6.6 1 5.9 7 5.9 6 5.4 9 5.9	<u>SD</u> To 3.7 2 6.4 2.3 1.7	tal Weig 36 24.6 61 4.6 96 5.0	IN, Fixed, 95% 0.70 [-0.03, 1.4] -0.70 [-2.39, 0.9] 1.20 [-0.42, 2.8] 0.50 [-0.29, 1.2] -0.20 [-1.06, 0.6]	e Cl 3] 9] 2] 9] 6]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference
Total events Heterogeneily. Chi ^a = Test for overall effect: (d) <u>Study or Subgroup</u> Andrilli 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.2 7.1 5.9 5.7	Regimen SD Tota 4.4 23 2.1 6 7.8 9 2.8 6 2.5 6	Standar Mean 8 6.6 1 5.9 7 5.9 6 5.4 9 5.9 8 4.17	SD Te 3.7 2 6.4 2.3 1.7 2.7 1.72 2.7	tal Weig 36 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5	IV. Fixed, 95% 0.70 [-0.03, 1.4] -0.70 [-2.39, 0.9] 1.20 [-0.42, 2.8] 0.50 [-0.29, 1.2] -0.20 [-1.06, 0.6] 0.24 [-0.46, 0.9]	8 3] 9] 2] 9] 6] 4]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference
Total events Heterogeneity: Chi# = Test for overall effect: (d) Study or Subaroup Andriulli 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Yüksel 2008 Total (95% Cl)	5.58, df = 7 Z = 0.84 (P <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41	Regimen SD Tota 4.4 23 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 57	Standar Mean 6 66 1 5.9 7 5.9 6 5.4 9 5.9 8 4.17 9	SD Te 3.7 2 6.4 2.3 1.7 2.7 1.72 2.7	tal Weig 36 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5	IN, Fixed, 95% 0.70 [-0.03, 1.4] -0.70 [-2.39, 0.9] 1.20 [-0.42, 2.8] 0.50 [-0.29, 1.2] -0.20 [-1.06, 0.6]	2] 3] 9] 2] 9] 6] 4] 0]	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chiª = Test for overall effect: (d) Study or Subgroup Andrilli 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Yüksel 2008	5.58, df = 7 Z = 0.84 (P <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41 5.23, df = 5	Regimen <u>SD</u> Tota 4.4 23: 2.1 6 7.8 9 2.8 6 2.5 6: 1.82 4: 57? (P = 0.39);	Standar Mean 6 66 1 5.9 7 5.9 6 5.4 9 5.9 8 4.17 9	SD Te 3.7 2 6.4 2.3 1.7 2.7 1.72 2.7	tal Weig 36 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5	IV. Fixed, 95% 0.70 [-0.03, 1.4] -0.70 [-2.39, 0.9] 1.20 [-0.42, 2.8] 0.50 [-0.29, 1.2] -0.20 [-1.06, 0.6] 0.24 [-0.46, 0.9]	8 3] 9] 2] 9] 6] 4]	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi# = Test for overall effect: (d) Study or Subgroup Andriull 2008 Chan 2011 Chan 2011 Chan 2011 Udd 2001 Yüksel 2008 Total (95% CI) Heterogeneity: Chi#=	5.58, df = 7 Z = 0.84 (P <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41 5.23, df = 5	Regimen <u>SD</u> Tota 4.4 23: 2.1 6 7.8 9 2.8 6 2.5 6: 1.82 4: 57? (P = 0.39);	Standar Mean 6 66 1 5.9 7 5.9 6 5.4 9 5.9 8 4.17 9	SD Te 3.7 2 6.4 2.3 1.7 2.7 1.72 2.7	tal Weig 36 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5	IV. Fixed, 95% 0.70 [-0.03, 1.4] -0.70 [-2.39, 0.9] 1.20 [-0.42, 2.8] 0.50 [-0.29, 1.2] -0.20 [-1.06, 0.6] 0.24 [-0.46, 0.9]	2] 3] 9] 2] 9] 6] 4] 0]	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi# = Test for overall effect: (d) Study or Subgroup Andriull 2008 Chan 2011 Chan 2011 Chan 2011 Udd 2001 Yüksel 2008 Total (95% CI) Heterogeneity: Chi#=	5.58, df = 7 Z = 0.84 (P <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41 5.23, df = 5 Z = 1.80 (P	Regimen <u>SD</u> Tota 4.4 23 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 57' (P = 0.39); = 0.07)	Standar 1 Mean 3 6.6 1 5.9 5 5.4 9 5.9 8 4.17 9 =	<u>SD</u> Te 3.7 2 6.4 2.3 1.7 2.7 1.72 5	tal Weig 36 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5 581 100.0	IV. Fixed, 95% 0.70 [-0.03, 1.4] -0.70 [-2.39, 0.9] 1.20 [-0.42, 2.8] 0.50 [-0.29, 1.2] -0.20 [-1.06, 0.6] 0.24 [-0.46, 0.9]	≥ 3 9 2 9 6 6 4 1 -4	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ^a = Test for overall effect. (d) <u>Study or Subgroup</u> Andriull 2008 Chan 2011 Chan 2011 Chan 2011 Udd 2001 Yüksel 2008 Total (95% CI) Heterogeneity: Chi ^a = Test for overall effect.	5.58, df = 7 Z = 0.84 (P: <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41 5.23, df = 5 Z = 1.80 (P	Regimen SD Tota 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 57 (P = 0.39); = 0.07) e	Standar a Mean 3 6.6 1 5.9 5 5.4 3 5.9 3 4.17 3 = 4%	SD Tc 3.7 2 6.4 2.3 1.7 2.7 1.72 5	tal Weig 236 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5 581 100.0 n	Itt IV, Fixed, 95%. % 0.701 p-0.31, 41 % 0.701 p-2.39, 10 % 0.701 p-2.39, 10 % 1.201 p-0.42, 2.8 % 0.501 p-0.29, 1.2 % 0.201 p-1.06, 0.6 % 0.201 p-1.06, 0.6 % 0.21 p-0.03, 0.7 Mean Difference	e CI 3] 9] 2] 9] 6] 4] -4 -4	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ² = Test for overall effect: (d) Study or Subaroup Andriull 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Yüksel 2008 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect: (e) Study or Subaroup	5.58, df = 7 Z = 0.84 (P: <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41 5.23, df = 5 Z = 1.80 (P <u>Intensive</u> <u>Mean</u>	Ender September 2014	Standar a Mean a 6.6 1 5.9 5 5.4 a 5.9 a 5.9	SD To 3.7 2 6.4 2.3 1.7 2.7 1.7 5 rd Regimee SD SD T	tal Weig 236 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5 81 100.0 n otal Wei	Int Int. Fixed, 95% % 0.70 [+0.03, 14] % 0.70 [+2.39, 0.9] % 0.70 [+2.39, 0.9] % 0.70 [+2.39, 0.9] % 0.70 [+0.23, 1.9] % 0.50 [+0.29, 1.2] % 0.50 [+0.20, 1.2] % 0.20 [+1.06, 0.6] % 0.24 [+0.46, 0.9] Mean Difference Mc. Fixed, 95%	e CI 3] 9] 2] 9] 6] 4] -4 •e CI	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ^a = Test for overall effect: (d) <u>Study or Subgroup</u> Andriull 2008 Chan 2011 Chan 2011 Chan 2011 Udd 2001 Yüksel 2008 Total (95% CI) Heterogeneity: Chi ^a = Test for overall effect (e) <u>Study or Subgroup</u> Andriulli 2008	5.58, df = 7 Z = 0.84 (P <u>Mean</u> 7.3 5.2 7.1 5.2 7.1 5.7 4.41 5.23, df = 5 Z = 1.80 (P <u>Intensive</u> <u>Mean</u> 1.7	Regimen SD Tota 4.4 23 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 57'(P = 0.39); = 0.07) e Regimen SD Tot 2.1 2.1	Standar a Mean b 6.6 1 5.9 5 5.4 3 5.9 4 4.17 9 = 2 4% Standa Mean 10 1.5	SD To 3.7 2 6.4 2.3 1.7 2.7 1.7 2.7 1.72 5 rd Regimee SD T 2.1 2.1	tal Weig 236 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5 81 100.0 n otal Weig 236 43.	Mexed, 95% 0.70 [+0.03, 1, 4] 0.70 [+2.39, 0] 0.70 [+2.39, 0] 0.70 [+2.39, 0] 0.70 [+2.39, 0] 0.50 [+0.29, 12] 0.50 [+0.29, 12] 0.50 [+0.29, 12] 0.20 [+1.06, 0.6] 0.21 [+0.46, 0.9] Mean Difference Mean Difference Mean Difference 0.20 [+0.18, 0]	e <u>C1</u> 3] 9] 2] 9] 9] 6] 4] 4] -4 -4 -6 <u>C1</u> -58]	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ² = Test for overall effect: d) <u>Study or Subgroup</u> Andriull 2008 Chan 2011 Chen 2012 Chen 2012 Chen 2012 Chen 2014 Udd 2001 Yüksel 2008 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect e) <u>Study or Subgroup</u> Andriulli 2008 Chan 2011	5.58, df = 7 Z = 0.84 (P : <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41 5.23, df = 5 Z = 1.80 (P <u>Intensive</u> <u>Mean</u> 1.7 2.4	Regimen SD Tota 4.4 23 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 577 (P = 0.39); = 0.07) • e Regimen SD SD Tot 2.1 2	Standar 4 Mean 8 6.6 5 5.9 7 5.9 5 5.4 9 5.9 8 4.17 9 7 9 5.9 8 4.17 9 5.9 8 4.17 9 5.9 8 4.17 9 5.9 8 1.7 10 1.5 11 2.1	<u>SD</u> To 3.7 2 6.4 2.3 1.7 2.7 1.72 5 rd Regime <u>SD</u> T 2.1 1.7 1.72	tal Weig (36 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5 81 100.0 n otal Weig 236 43. 61 14.	IM R.Freed. 95%. 0.70 { 10.03, 14 0.70 { 10.03, 14 % 0.70 { 10.23, 10.03, 14 % 0.50 { 10.24, 12, 12, 10.03, 10.03, 10.01, 10.03, 10.03, 10.01, 10.03, 10.03, 10.01, 10.	e <u>C1</u> 3] 9] 2] 9] 9] 9] 4] -4 <u>e</u> <u>C1</u> 58] 96]	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity, Chi ^a = Test for overall effect: d) Study of Subgroup Andriull 2008 Chan 2011 Chan 2011 Chan 2011 Udd 2001 Yüksel 2008 Total (95% Ch) Heterogeneity, Chi ^a = Test for overall effect e) Study of Subgroup Andriulli 2008 Chan 2011	5.58, df = 7 Z = 0.84 (P : <u>Mean</u> 7.3 5.2 7.1 5.23, df = 5 Z = 1.80 (P <u>Intensiv</u> 1.7 2.4 2.9	SD Tota 4.4 23 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 577'(P = 0.39); = 0.07) e Regiment SD 2.1 23 2.1 22 2.1 22 6.2 5	Standar a Mean 3 6.6 1 5.9 7 5.9 5 5.4 9 5.9 8 4.17 9 = 9 5.9 10 1.5 10 1.5 11 2.1 7 1.6	<u>SD</u> To 3.7 2 6.4 2.3 1.7 2.7 1.72 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	tal Weig 336 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5 581 100.0 0 49 236 43. 61 14. 96 3.	Mexed.95% 0.70 [+0.03, 1.4] % 0.70 [+2.39, 0.9] % 0.70 [+2.39, 0.9] % 0.70 [+2.39, 0.9] % 0.50 [+0.23, 1.6] % 0.50 [+0.24, 1.2] % 0.50 [+0.29, 1.2] % 0.20 [+1.06, 0.6] % 0.21 [+0.46, 0.9] % 0.33 [+0.03, 0.7] Mean Difference 1.01 [+0.18, 0.5] % 0.20 [+0.18, 0.5] % 0.20 [+0.18, 0.5]	e <u>CI</u> 3] 9] 9] 6] 4] -4 -4 -4 -4 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: Chi ² = Test for overall effect: d) <u>Study or Subgroup</u> Andriull 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Yüksel 2008 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect e) <u>Study or Subgroup</u> Andrulli 2008 Chan 2011 Chen 2012 Chan 2011 Chen 2012	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.2 7.1 5.2 5.7 4.41 5.23, df = 5 Z = 1.80 (P <u>Intensive</u> <u>Mean</u> 1.7 2.4 2.9 3.3	Regimen SD Tota 4.4 23 2.1 6 7.8 9 2.5 6 2.5 6 2.5 6 2.5 6 2.5 0 9 0.3 9 0.07)	Standar 1 Mean 3 6.6 1 5.9 5 5.4 9 5.9 3 4.17 9 3 = 4% Standa Mean 18 1.5 12.1 2.1 17 1.6 13 2.82	SD To 3.7 2 6.4 2.3 1.7 2.7 1.7 1.7 1.72 5 rd Regimet SD SD T 2.1 1.7 2.2 1.73	tal Weig 36 24.6 61 4.6 96 5.0.0 66 21.1 73 18.0 49 26.5 81 100.0 n otal Weig 236 43. 61 14. 96 3. 83 22:	Mexed. 95%. 0.70 0.03, 1.4 9.070 0.03, 1.4 9.070 0.03, 1.4 9.070 0.03, 0.4 9.020 0.02, 0.2 9.021 0.06, 0.2 9.024 0.46, 0.9 Wean Difference 1 Mean Difference 1 M. Fixed. 95% 95 95 95 95 95 95 95 95 95 95 96 97 98 99 90 90 91 92 93 94 95 95 91 92 94 94 95 94 95 95 95 94 94 95 94 94<	e CI 3] 9] 2] 9] 6] 4] -4 -4 -6 -6] -6] -4 -6 -6] -6] -6] -6] -6] -6] -6]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference N. Fixed, 95% CI
Total events Heterogeneity: Chi ² = Test for overall effect: d) <u>Study or Subaroup</u> Andriuli 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Yüksel 2008 Total (95% cf) Heterogeneity: Chi ² = Test for overall effect e) <u>Study or Subaroup</u> Andriuli 2008 Chan 2011 Masjedizadeh 2014	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.2 7.1 5.2 7.1 5.7 4.41 5.23, df = 5 Z = 1.80 (P Intensive Mean 1.7 2.9 3.3 3.8	Regimen SD Tota 4.4 23: 2.1 6 7.8 9 2.8 6: 2.5 6: 1.82 4: 57'(P=0.39); = = 0.07) = e Regimen SD SD Tot 2.1 2: 6.2 5 1.71 8 3.8 6''	Standar a Mean 3 6.6 1 5.9 7 5.9 6 5.4 9 4.17 9 # # 4% Standa Mean 18 1.5 11 2.1 17 1.6 13 2.82 6 3.1	SD To 3.7 2 6.4 2.3 1.7 2.7 1.72 5 rd Regime 5 SD 1 2.1 1.7 2.5 1.7	tal Weig 36 24.6 61 4.6 96 5.0 66 21.1 73 18.0 49 26.5 81 100.0 n otal Weig 236 43. 61 14. 96 3. 83 222. 66 5.	It M. Extend. 95%. 0.70 (2.39, 0.9) 0.70 (2.239, 0.9) 1.70 (2.239, 0.9) 0.50 (2.239, 0.9) 0.70 (2.239, 0.9) 0.50 (2.029, 1.2) 0.50 (2.029, 1.2) 0.50 (2.029, 1.2) % 0.20 (1.10, 0.6) % 0.20 (1.10, 0.6) % 0.21 (1.06, 0.6) % 0.22 (1.06, 0.6) % 0.23 (1.0.03, 0.7) Mean Difference 1.00 (1.00, 0.7) % 0.20 (1.10, 0.5) 0.30 (1.03, 0.7) 1.30 (1.00, 1.2) % 0.20 (1.10, 0.1) % 0.20 (1.10, 0.1) % 0.48 (1.00, 1.2)	e <u>CI</u> 33 99 93 96 61 44 -4 -4 -6 -6 -6 -6 -6 -6 -6 -6 -6 -6	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference N. Fixed, 95% CI
Total events Heterogeneity: Chi ² = Test for overall effect: (d) Study or Subgroup Andriulli 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Yüksel 2008 Total (95% Cl) Heterogeneity: Chi ² = Test for overall effect (e) Study or Subgroup Andrulli 2008 Chan 2011 Chen 2012 Chan 2011 Chen 2012	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.2 7.1 5.2 5.7 4.41 5.23, df = 5 Z = 1.80 (P <u>Intensive</u> <u>Mean</u> 1.7 2.4 2.9 3.3	Regimen SD Tota 4.4 23: 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 577 (P = 0.39); (P = 0.39); = 0.07) e Regimen SD 2.1 23: 2.1 22: 2.2 2 2.1 23: 3.8 6 3.8 6 7.7 6	Standar 1 Mean 3 6.6 1 5.9 5 5.4 9 5.9 3 4.17 9 3 = 4% Standa Mean 18 1.5 12.1 2.1 17 1.6 13 2.82	SD To 3.7 2 6.4 2.3 1.7 2.7 1.7 1.7 1.72 5 rd Regimet SD SD T 2.1 1.7 2.2 1.73	tal Weig 336 24.6 61 4.8 96 5.0 66 21.1 73 18.0 49 26.5 81 100.0 0 49 236 43. 61 14.4 96 3. 83 22.6 66 5. 73 1.1	Mexed. 95%. 0.70 0.03, 1.4 9.070 0.03, 1.4 9.070 0.03, 1.4 9.070 0.03, 0.4 9.020 0.02, 0.2 9.021 0.06, 0.2 9.024 0.46, 0.9 Wean Difference 1 Mean Difference 1 M. Fixed. 95% 95 95 95 95 95 95 95 95 95 95 96 97 98 99 90 90 91 92 93 94 95 95 91 92 94 94 95 94 95 95 95 94 94 95 94 94<	e CI 3] 9] 2] 9] 2] 9] 4] -4 -4 -4 -6 -6 -6 -6 -6 -6 -6 -6 -7 -7 -7 -7 -7 -7 -7 -7 -7 -7	Favours [Intensive Regimen] Favours [Standard Regimen]
Total events Heterogeneity: ChiP = Test for overall effect: d) Study or Subgroup Andrulli 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Heterogeneity: ChiP = Test for overall effect: e) Study or Subgroup Andrulli 2008 Chan 2011 Chen 2012 Masjedizadeh 2014 Songür 2011 Udd 2001 Yüksel 2008	5.58, df = 7 Z = 0.84 (P <u>Mean</u> 7.3 5.2 7.1 5.9 5.7 4.41 5.23, df = 5 Z = 1.80 (P <u>Mean</u> 1.7 2.4 2.9 3.3 3.8 5.3	Regimen SD Tota 4.4 23 2.1 6 7.8 9 2.8 6 2.5 6 1.82 4 577 (P = 0.39); = 0.07) e Regimen SD Tot 2.1 2.2 2.1 2.1 2.1 2.4 3.8 6 7.7 6 2.4 4	Standar 4 Mean 5 9 7 5.9 5 5.4 9 5.9 8 4.17 9 5.9 # #ean 4% Standa Mean 18 1.5 13 2.82 16 3.1 19 5.5 18 2.18	SD To 3.7 2 6.4 2.3 1.7 2.7 1.7 2.7 1.72 5 rd Regimeer SD T 2.1 1.7 2.2 1.7 2.2 1.7 2.5 5.2 1.89	tal Weig 336 24.6 61 4.8 96 5.0 66 21.1 73 18.0 49 26.5 81 100.0 0 236 236 43. 83 22. 66 5. 73 1. 49 8.	M. Reed. 95%. 0.70 { F0.03, 1, 4 0.70 { F0.03, 1, 4 0.70 { F0.03, 1, 4 1.20 { F0.3, 1, 2 0.50 { F0.2, 20, 0, 3 0.50 { F0.2, 1, 20, 0, 3 0.50 { F0.2, 1, 20, 0, 3 0.50 { F0.2, 1, 20, 0, 3 0.33 { F0.03, 0, 7 Mean Difference alt N. Fixed, 95% 0.20 { F0.16, 0, 1, 3 0.30 { F0.3, 6, 0, 7 3.3 { F0.03, 0, 7 0.33 { F0.03, 0, 7 0.30 { F0.3, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	e CI 3] 9] 2] 9] 6] 4] 4] -4 -4 -6 58] 96] 58] 96] 96] 96] 96] 97] 727]	Favours [Intensive Regimen] Favours [Standard Regimen] Mean Difference N. Fixed, 95% CI
Total events Heterogeneity: ChiP = Test for overall effect: d) Study or Subgroup Andriull 2008 Chan 2011 Chen 2012 Songür 2011 Udd 2001 Yüksel 2008 Total (95% Cl) Heterogeneity: ChiP = Test for overall effect e) Study or Subgroup Andriull 2008 Chan 2011 Chen 2012 Chas 2011 Chen 2012 Chas 2014 Chas 2014 Chas 2014	5.58, df = 7 Z = 0.84 (P Mean 7.3 5.7 4.41 5.23, df = 5 Z = 1.80 (P intensive Mean 1.7 2.4 3.3 3.8 5.3 2.59	Regimen SD Tota SD Tota 70 A4 23 21 6 7.8 9 2.8 6 2.5 6 1.82 4 577 (P = 0.39); 'I 577 e Regimen SD Tot 2.1 22 2 6 6.2 2 1.71 2 3.8 6 7.7 6 2.4 66 66	Standar 4 Mean 8 6.6 5 5.9 5 5.4 9 5.9 8 4.17 9 3 18 1.5 17 1.6 12.11 1.7 18 2.92 16 3.1 19 5.5 18 2.18 18 2.18	SD To 3.7 2 6.4 2.3 1.7 2.7 1.7 2.7 1.72 5 rd Regimeer SD T 2.1 1.7 2.2 1.7 2.2 1.7 2.5 5.2 1.89	tal Weig 336 24.6 61 4.8 96 5.0 66 21.1 73 18.0 49 26.5 881 100.0 0 49 236 43. 61 14.4 96 3. 83 22.6 66 5. 73 1.1	M. Reed. 95%. 0.70 { F0.03, 1, 4 0.70 { F0.03, 1, 4 0.70 { F0.03, 1, 4 1.20 { F0.3, 1, 2 0.50 { F0.2, 20, 0, 3 0.50 { F0.2, 1, 20, 0, 3 0.50 { F0.2, 1, 20, 0, 3 0.50 { F0.2, 1, 20, 0, 3 0.33 { F0.03, 0, 7 Mean Difference alt N. Fixed, 95% 0.20 { F0.16, 0, 1, 3 0.30 { F0.3, 6, 0, 7 3.3 { F0.03, 0, 7 0.33 { F0.03, 0, 7 0.30 { F0.3, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,	e CI 3] 9] 2] 9] 6] 4] 4] -4 -4 -6 58] 96] 58] 96] 96] 96] 96] 97] 727]	Favours [Intensive Regimen] Favours [Standard Regimen]

Figure 3. Forest plots of meta-analysis comparing intensive versus standard proton pump inhibitor regimens. (a) Re-bleeding; (b) operation intervention; (c) postoperative mortality; (d) hospital stays; (e) blood transfusion volume.

M-H, Mantel-Haenszel; Cl, confidence interval.

	Test	t	95% CI	Р
Re-bleeding	Begg's test			0.438
-	Egger's test	0.38	-0.15, 0.92	0.561
Operation intervention	Begg's test			0.631
	Egger's test	0.93	- 1.86 , 1.97	1.000
Postoperative mortality	Begg's test			0.253
	Egger's test	0.97	-1.13, 1.89	0.841
Hospital stay	Begg's test			0.533
. ,	Egger's test	0.62	-1.03, 1.54	0.651
Blood transfusion volume	Begg's test			0.431
	Egger's test	0.51	-0.87, I.23	0.549

Table 2. Publication bias analysis of the meta-analysis.

CI, confidence interval.

ulcer bleeding. A meta-analysis of the available data found no significant differences between the two groups in terms of the incidence of postoperative re-bleeding, surgical intervention, postoperative mortality, and hospital stay, but the volume of blood transfusion differed significantly between the two groups. The volume of blood transfusion in the high-dose group was higher than that in the low-dose group, indicating that high-dose PPIs might not have a better effect on gastrointestinal ulcer bleeding than low-dose PPIs. This result differed from the results of RCTs published in 2010 and 2018, which found that low-dose PPI treatment was equally effective to highdose PPI treatment following endoscopic arrest of bleeding.^{31,32} As shown by Wang et al.,³³ the current analysis found that high-dose PPIs had no effects compared with low-dose PPIs on the incidences of re-bleeding, operation intervention, postoperative mortality, and hospital stay in patients treated with endoscopic hemostasis of gastrointestinal bleeding,³³ while another study also found no difference between intermittent and continuous PPI therapy in patients with high-risk bleeding ulcers.³⁴

This meta-analysis also had some limitations. The results of the PPI therapy statistical heterogeneity were limited in RCTs, and the limited evidence of a dosedependent effect of PPI therapy shed some doubt on the reliability of the findings. Second, the included studies were all published papers and grey literature was not analyzed, leading to possible publication bias. Third, the type and administration method of the PPIs used in the studies were not completely consistent, which may have increased the clinical heterogeneity. Fourth, some data could not be extracted and included in the meta-analysis because of limitations in the original data. Further clinical research and evaluation are therefore needed to verify the current results and to evaluate the effects of the two administration schedules on the prevention of postoperative long-term complications.

The current findings indicate that there is no significant difference between high-dose PPI infusion therapy and low-dose PPI treatment in terms of re-bleeding, duration of hospitalization, need for surgery, and mortality among patients receiving endoscopic hemostasis for gastrointestinal bleeding. However, further studies with well-designed rigorous trial plans are needed to increase the sample size, and the results need to be verified by more high-quality clinical studies with long-term follow-up.

Declaration of conflicting interest

There are no conflicts of interest. This manuscript will be registered in PROSPERO in the future.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD

Liang Chen D https://orcid.org/0000-0002-6135-617X

Supplemental material

Supplemental material for this article is available online.

References

- Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. *BMJ* 1995; 311: 222–226.
- Christensen A, Bousfield R and Christiansen J. Incidence of perforated and bleeding peptic ulcers before and after the introduction of H2-receptor antagonists. *Ann Surg* 1988; 207: 4–6.
- Cook DJ, Guyatt GH, Salena BJ, et al. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a metaanalysis. *Gastroenterology* 1992; 102: 139–148.
- Marmo R, Rotondano G, Piscopo R, et al. Dual therapy versus monotherapy in the endoscopic treatment of high-risk bleeding ulcers: a meta-analysis of controlled trials. *Am J Gastroenterol* 2007; 102: 279–289.
- Sung JJ, Tsoi KK, Lai LH, et al. Endoscopic clipping versus injection and thermocoagulation in the treatment of nonvariceal upper gastrointestinal bleeding: a meta-analysis. *Gut* 2007; 56: 1364–1373.

- Green FW Jr, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. *Gastroenterology* 1978; 74: 38–43.
- Reynolds JR, Walt RP, Clark AG, et al. Intragastric pH monitoring in acute upper gastrointestinal bleeding and the effect of intravenous cimetidine and ranitidine. *Aliment Pharmacol Ther* 1987; 1: 23–30.
- Berardi RR and Welage LS. Proton-pump inhibitors in acid-related diseases. *Am J Health Syst Pharm* 1998; 55: 2289–2298.
- Lin HJ, Lo WC, Lee FY, et al. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. *Arch Intern Med* 1998; 158: 54–58.
- Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+, K+ ATPase. *Annu Rev Pharmacol Toxicol* 1995; 35: 277–305.
- Barkun AN, Bardou M, Kuipers EJ, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding; *Ann Intern Med* 2010; 152: 101–113.
- Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557–560.
- Udd M, Miettinen P, Palmu A, et al. Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: a prospective randomized double-blind study. *Scand J Gastroenterol* 2001; 36: 1332–1338.
- 14. Chan WH, Khin LW, Chung YF, et al. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. *Br J Surg* 2011; 98: 640–644.
- 15. Chen CC, Lee JY, Fang YJ, et al. Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. *Aliment Pharmacol Ther* 2012; 35: 894–903.

- Hsu YC, Perng CL, Yang TH, et al. A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding. *Br J Clin Pharmacol* 2010; 69: 245–251.
- Liu N, Liu L, Zhang H, et al. Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. J Gastroenterol Hepatol 2012; 27: 1473–1479.
- Songur Y, Balkarli A, Acarturk G, et al. Comparison of infusion or low-dose proton pump inhibitor treatments in upper gastrointestinal system bleeding. *Eur J Intern Med* 2011; 22: 200–204.
- Yuksel I, Ataseven H, Koklu S, et al. Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: a prospective randomized study. *Digestion* 2008; 78: 39–43.
- Andriulli A, Loperfido S, Focareta R, et al. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. *Am J Gastroenterol* 2008; 103: 3011–3018.
- Masjedizadeh AR, Hajiani E, Alavinejad P, et al. High dose versus low dose intravenous pantoprazole in bleeding peptic ulcer: a randomized clinical trial. *Middle East J Dig Dis* 2014; 6: 137–143.
- 22. Laine L and McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidencebased approach based on meta-analyses of randomized controlled trials. *Clin Gastroenterol Hepatol* 2009; 7: 33–47.
- 23. Kim JI, Cheung DY, Cho SH, et al. Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial. *Dig Dis Sci* 2007; 52: 3371–3376.
- Metz DC, Ferron GM, Paul J, et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. *J Clin Pharmacol* 2002; 42: 512–519.
- Laine L and Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol 2012; 107: 345–360.
- Barkun AN, Herba K, Adam V, et al. Highdose intravenous proton pump inhibition

following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis. *Aliment Pharmacol Ther* 2004; 19: 591–600.

- 27. Lee KK, You JH, Wong IC, et al. Costeffectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. *Gastrointest Endosc* 2003; 57: 160–164.
- Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized doubleblind placebo-controlled multicentre study. *Scand J Gastroenterol* 1997; 32: 320–327.
- 29. Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. *Scand J Gastroenterol* 1997; 32: 328–333.
- Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. *N Engl J Med* 2000; 343: 310–316.
- Sgourakis G, Chatzidakis G, Poulou A, et al. High-dose vs. low-dose proton pump inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer. A metaanalysis and meta-regression analysis. *Turk J Gastroenterol* 2018; 29: 22–31.
- Wu LC, Cao YF, Huang JH, et al. Highdose vs low-dose proton pump inhibitors for upper gastrointestinal bleeding: a metaanalysis. *World J Gastroenterol* 2010; 16: 2558–2565.
- 33. Wang CH, Ma MHM, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med* 2010; 170: 751–758.
- 34. Sachar H, Vaidya K and Laine L. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med 2014; 174: 1755–1762.